Office of Research & Development |
  |
Talk to the Veterans Crisis Line now
An official website of the United States government
Project Number: | I01CX001814-01 |
| Title: | Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance inPosttraumatic Stress |
| Principal Investigator: | Sabra S Inslicht |
| Location: | San Francisco, CA |
| Congressional District Code: | 12 |
| Research Service: | Clinical Science R&D |
| Project Period: | January 2019 - December 2024 |
| FY 2021 Funding Amount: | $296,875 |
| Total Award Amount (all years): |
$4,186,725 |
| Abstract: |
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt: Posttraumatic stress disorder (PTSD) is a common consequence of combat that is manifested in part by trauma-related hyperarousal and reactivity, seen in increased startle responses and impaired sleep that result from central and autonomic nervous system alterations. In fact, disturbed sleep is the most prevalent symptom endorsed by PTSD patients and is potentially debilitating in many domains of functioning (1, 2). As a relatively non-stigmatizing symptom, it is no surprise that disturbed sleep... |